与此同时，该基金最新成交量为3.96亿份，最新成交额跌破8.00亿元，全市场排名较上一交易日后退32 位。 2025年10月9日，恒生创新药ETF（520500.SH）收跌1.36%，主力资金（单笔成交额100万元以上）净流 出4163.01万元，居全市场第一梯队。 ...

Group 1 - The overall sentiment among brokerages is discussing holding stocks or cash during the holiday, as well as the calendar effect in October [1][5] - The strategy team from JianTou believes that liquidity tends to contract before the National Day holiday, but this is often a "sentimental contraction" [1] - The team from Huaxi suggests that as the holiday approaches, external funds may slow down entering the market, leading to a potential short-term adjustment in A-shares and Hong Kong stocks [1][5] Group 2 - The Guangfa strategy team found that since 2005, cyclical industries have over a 65% probability of rising in the fourth quarter, with more than 60% probability of outperforming the CSI 300 index [1][6] - Key sectors such as optical modules, PCBs, innovative pharmaceuticals, and colored metals are maintaining healthy trends, while sectors like automotive parts and robotics are experiencing relative stagnation [1][6] - The CITIC strategy team emphasizes that resource security, corporate overseas expansion, and technological competition remain crucial structural market clues [4] Group 3 - The market is expected to see a new upward momentum in October, driven by the upcoming third-quarter report trading window and significant policy expectations [5] - The strategy from Yinxing indicates that the market's risk appetite may increase due to the concentration of important meetings and events in October [5] - The strategy team from Zhongtai highlights that the current market levels still have strong support, and long-term capital remains inclined to invest [6]

2025年9月26日，恒生创新药ETF（520500.SH）收跌1.68%，主力资金（单笔成交额100万元以上）净流 出2826.30万元，居全市场第一梯队。 与此同时，该基金最新成交量为3.50亿份，最新成交额达6.75亿元，当日主力资金净流出成交额占比达 4.19%。 ...

Group 1 - The semiconductor ETFs experienced significant gains, with the chip leader ETF rising by 5% and the semiconductor equipment ETF soaring by 8% due to rumors about a domestically developed EUV lithography machine expected to enter trial production in Q3 2025 and achieve mass production in 2026 [1] - The current PE valuation of the chip index has reached 143 times, placing it in the 99th percentile, the highest level since the index's inception, even surpassing the peak in 2021 [2][4] - The PB valuation of the chip index stands at 7.46 times, which is in the 83.71 percentile, indicating that while it is not as high as the PE valuation, it is still at a historically elevated level [4] Group 2 - Despite the high valuations, many investors remain cautious due to past experiences with high-valuation sectors like liquor, healthcare, and new energy, where significant losses were incurred despite stable profit growth [6][9] - Companies like Kweichow Moutai and CATL have seen their PE valuations drop significantly, with Moutai's PE decreasing from 70 times to 20 times, while CATL's dropped from 160 times to 29 times, highlighting the impact of valuation on stock performance [8][11] - The trend model strategy is proposed as a solution for navigating high-valuation environments, allowing investors to hold onto stocks as long as they maintain an upward trend, thus avoiding significant losses during market downturns [14][17] Group 3 - Alibaba announced a significant investment of 380 billion in AI infrastructure and a partnership with NVIDIA, leading to a 10% increase in its stock price, although it still needs to rise 40% to reach its previous high [19] - The ongoing investment in new energy by China contrasts with the U.S. approach, which may lead to China dominating the global new energy sector in the future [19]

药捷安康近期股价走势 本报（chinatimes.net.cn）记者栗鹏菲 叶青 北京报道 一场围绕创新药企药捷安康的资本狂欢，在经历9月16日的"惊天"震荡后余波未平。截至2025年9月18日 收盘，药捷安康-B（2617.HK）的股价为183.2港元，当日跌幅为12.43%，较9月16日历史高点下跌超 70%，市值维持在727.12亿港元左右。 受药捷安康股价剧烈波动影响，作为跟踪国证港股通创新药指数的代表性产品，港股通创新药ETF （520880）在2025年9月15日至9月17日期间，连续三个交易日净值下跌，累计跌幅为2.4%。跟踪恒生 创新药指数的恒生创新药ETF（520500），同样累计跌幅为2.41%。 药捷安康股价异动的导火索，源于一则临床进展公告。9月10日，公司宣布核心产品替恩戈替尼联合疗 法获国家药监局临床默示许可。尽管消息面利好，公司基本面却未发生实质改变：截至今年6月末，公 司尚无药品上市销售，上半年营收为零，净亏损1.23亿元。在缺乏业绩支撑的背景下，其股价被资金迅 速推高后又急速回落，凸显出创新药领域投资的高风险特性。 资金推动下的估值泡沫：流通盘成炒作温床 药捷安康是一只典型的 ...

与此同时，该基金最新成交量为6.46亿份，最新成交额达13.02亿元。 2025年9月18日，恒生创新药ETF（520500.SH）收涨0.60%，主力资金（单笔成交额100万元以上）净流 出724.49万元。 ...

Group 1: ETF Market Overview - As of September 12, 2025, there are 1,292 ETFs in the Shanghai and Shenzhen markets, with a total asset management scale of 52,387.73 billion [2] - The breakdown of ETFs includes 1,029 stock ETFs (35,315.17 billion), 39 bond ETFs (5,718.88 billion), 27 money market ETFs (1,564.76 billion), 17 commodity ETFs (1,611.53 billion), 173 cross-border ETFs (8,120.58 billion), and 6 unlisted ETFs (52.32 billion) [2] - In the week from September 8 to September 12, 2025, four new stock ETFs were launched, including two fintech-themed ETFs, with a total issuance scale of 5.682 billion [3][4] Group 2: ETF Performance Analysis - The median weekly return for stock ETFs was 1.97%, with the best-performing ETF being the China United Asset Management's Sci-Tech Chip Design ETF, which rose by 10.14% [3][4] - Conversely, the worst performer was the Guotai Junan Sci-Tech Innovation Drug ETF, which fell by 3.12% [4] - The average share change for stock ETFs was an increase of 6.6576 million shares, with the chemical ETF seeing the largest increase of 2.968 billion shares [4] Group 3: PB-ROE Framework and ETF Rotation Strategy - The PB-ROE framework categorizes industries into six quadrants, focusing on high PB and high ROE industries in the third quadrant and low PB and medium ROE industries in the fifth quadrant [5] - Backtesting from 2017 to February 2024 shows that only the third and fifth quadrants achieved excess returns, with annualized excess returns of 4.27% and 1.55%, respectively [5] - The combined PB-ROE rotation strategy yielded an annualized return of 11.93% and an annualized excess return of 13.22% [6] Group 4: Investment Recommendations - The report recommends focusing on the automotive, transportation, and public utilities sectors, corresponding to their respective industry ETFs [8]

近期，伴随政策持续赋能与国际化进程加速，我国创新药产业迎来高质量发展新阶段。恒生创新药ETF （520500）作为聚焦港股创新药龙头企业的投资工具之一，正获得市场广泛关注。行业基本面向好，叠 加流动性预期改善，创新药板块配置价值或凸显。 政策来源：2025/9/12，国家药监局-《关于优化创新药临床试验审评审批有关事项的公告》 风险提示：基金有风险，投资需谨慎。如需购买相关基金产品，请您关注投资者适当性管理相关规定， 提前做好风险测评，并根据您自身的风险承受能力购买与之相匹配的风险等级的基金产品。基金的过往 业绩并不预示其未来表现，基金管理人管理的其他基金的业绩并不构成基金业绩表现的保证。基金投资 需注意投资风险，请仔细阅读基金合同、基金招募说明书和产品资料概要等法律文件，了解基金的具体 情况。本基金可投资于境外证券市场，还将面临汇率风险、境外证券市场风险等特殊投资风险。指数由 恒生指数公司编制并发布，其所有权归属恒生指数公司。指数由恒生指数有限公司（"恒生"）编制和计 算，其所有权归属恒生。恒生将采取一切必要措施以确保指数的准确性，但不对此作任何保证，亦不因 指数的任何错误对任何人负责。 MACD金叉信号形 ...

2025年9月16日，恒生创新药ETF（520500.SH）收跌1.37%，主力资金（单笔成交额100万元以上）净流 出2824.82万元，居全市场第一梯队。 与此同时，该基金最新成交量为3.35亿份，最新成交额跌破6.80亿元，全市场排名较上一交易日下降17 位。 ...

Core Viewpoint - The current market rally is primarily driven by companies with overseas exposure or those deeply integrated into global supply chains, necessitating a global perspective for evaluating fundamentals and liquidity [1][2][3] Group 1: Market Dynamics - The majority of the top-performing stocks since June are linked to overseas strategies, particularly in sectors like AI, innovative pharmaceuticals, and resource stocks with global pricing [2][3] - The market has shown rational behavior, with institutional funds driving the rally rather than retail investors, indicating a structural market rather than a speculative one [2][4] - The proportion of overseas revenue for A-share companies has increased from 12.6% to an estimated 19.4% by 2024, highlighting a shift towards global business perspectives [2][3] Group 2: Investment Strategy - The recommended investment focus should be on sectors with real profit generation and strong industry trends, including resources, consumer electronics, innovative pharmaceuticals, chemicals, gaming, and military industries [8][9] - The strategy emphasizes minimizing volatility and avoiding broad market exposure, instead concentrating on high-quality sectors [4][8] Group 3: Trading Activity - The average daily turnover rate for the A-share market has reached historically high levels, with a reasonable turnover rate estimated between 1.7% and 1.9% after accounting for emotional premiums [5][6] - Specific sectors such as dual innovation, electronics, non-ferrous metals, and military have seen significant increases in trading activity, indicating heightened investor interest [7][8] Group 4: Future Outlook - The future fundamentals will reflect the gradual realization of China's manufacturing competitiveness in global markets, particularly in sectors like robotics, gaming, and innovative pharmaceuticals [3][9] - Continued focus on industries with sustainable pricing power, such as rare earths and chemicals, is advised, as these sectors are expected to maintain profitability despite global economic fluctuations [9]